

ORIGINAL**Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine**

Michiyo Okazaki¹, Ichiro Shimizu², Momoko Ishikawa³, Soichiro Fujiwara³, Hirofumi Yamamoto³, Tatsuhiko Shiraishi³, Takahiro Horie³, Arata Iuchi³, and Susumu Ito²

¹Department of Gastroenterology, Kochi Red Cross Hospital, Kochi, Japan, ²Department of Digestive and Cardiovascular Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan ; and ³Department of Internal Medicine, Tokushima Prefectural Miyoshi Hospital, Tokushima, Japan

Abstract :

AIM : Prostaglandins (PGs) and leukotrienes (LTs) are major factors involved in the defense of the gastric mucosa against ulcer formation. However, little is still known about the gastromucosa-protecting action of proton pump inhibitors (PPIs) and histamine H₂ receptor antagonists (H₂ blockers) in patients with gastric ulcer. We therefore examined the effectiveness of a PPI in protecting the gastric mucosa.

METHODS : We compared the PGE₂ and LTB₄ levels and the expression levels of cyclooxygenase (COX)-1 and COX-2 mRNA in the gastric mucosa in gastric ulcer patients between the group treated for 8 weeks with a PPI, rabeprazole (PPI group ; n=5), and the group treated for 8 weeks with an H₂ blocker, ranitidine (H₂ blocker group ; n=6), as well as in nonulcer subjects (control group ; n=5).

RESULTS : The mucosal levels of PGE₂ and COX-2 mRNA expression were significantly lower in the ulcer patients than those in the nonulcer patients, whereas the LTB₄ level was significantly higher in the ulcer patients than that in the nonulcer patients, and it was also significantly lower in the ulcerated mucosa than that in the nonulcerated mucosa. The PPI group had a significantly increased PGE₂ and decreased LTB₄ levels in comparison to the H₂ blocker group during the ulcer-healing stage. The COX-1 mRNA expression showed no difference among the PPI and H₂ blocker groups or between before and after the treatment. However, the COX-2 mRNA expression increased in the PPI group more than that in the H₂ blocker group during the ulcer-healing stage.

CONCLUSION : These findings demonstrated the significant gastric-mucosa-protecting effect of PPI by increasing the PGE₂ production and reducing the LTB₄ production. *J. Med. Invest.* 54 : 83-90, February, 2007

Keywords : rabeprazole, COX-2, PGE₂, LTB₄, H₂ blocker

Received for publication November 30, 2006 ; accepted December 20, 2006.

Address correspondence and reprint requests to Ichiro Shimizu, M.D., Department of Digestive and Cardiovascular Medicine, Institute of Health Biosciences The University of Tokushima Graduate School, Kuramoto-cho, Tokushima 770-8503, Japan and Fax : 81-88-633-9235

INTRODUCTION

Proton pump inhibitors (PPIs) are more potent than histamine H₂ receptor antagonists (H₂ blockers) in terms of their ability to inhibit gastric acid secretion while also promoting the healing of gas-

tric ulcers(1). PPIs block the final step in acid secretion from gastric parietal cells. Rabeprazole is a substituted benzimidazole PPI. In addition to its inhibitory effect on gastric acid secretion, rabeprazole has been reported to prevent gastric mucosal damage such as that resulting from ethanol or aspirin administration in animal models(2-4). Lansoprazole, one of PPIs, has also been reported to induce gastric mucosal protection through up-regulation of cyclooxygenase (COX)-2 with endogenous prostaglandin (PG) synthesis in an animal model of gastric mucosal injury(5). COX is the enzyme that catalyzes the committed step in the metabolism of arachidonic acid to PGs(6). Two isoforms of COX exist: including constitutively expressed COX-1 and inducible COX-2 in stomach. PGs play an important role in the gastric mucosal defense (7). It should be noted that increased PG synthesis via the COX-2 expression and decreased leukotriene (LT) synthesis in the gastric mucosa may be involved in mucosal cytoprotection(8). LTs belong to a group of proinflammatory mediators derived from arachidonic acid(9, 10). However, little is still known about the gastromucosa-protecting action of PPIs and H₂ blockers in patients with gastric ulcer.

We experienced a case who demonstrated a very large gastric ulcer which perforated the abdominal wall and had been caused by diclofenac, a nonsteroidal anti-inflammatory drug (NSAID)(11). In this case, since conservative treatment by the oral administration of the H₂ blocker ranitidine and a PG preparation did not show any sign of closure of the perforation, ranitidine was replaced by rabeprazole. Thereafter, the mucosal regeneration progressed rapidly, the perforation closed, and the ulcer completely healed. These findings suggested that not only the PG preparation but also rabeprazole thus appears to promote cytoprotection against the gastric mucosal injury. Therefore, in order to clarify the differences between the gastromucosa-protecting actions of rabeprazole and ranitidine in patients with gastric ulcer, we administered either rabeprazole or ranitidine to patients having their first episodes

of gastric ulcer for 8 weeks and then comparatively evaluated the expression of gastric mucosal COX and the secretory kinetics of PGs and LTs. To balance the background of damage to the gastric mucosa, the subjects were limited to patients who were positive for *Helicobacter pylori* (*Hp*).

SUBJECTS AND METHODS

Subjects

From September 2000 to December 2002, the study was conducted at Tokushima Prefecture Miyoshi Hospital. The subjects consisted of 11 patients who demonstrated their first episode of gastric ulcer with no previous history of the disease in whom a single acute stage (A1 or A2) ulcer was located at the gastric angle without any bleeding, and the presence of *Hp* was confirmed by the ¹³C-urea breath test (Otsuka Pharmaceutical Co., Tokyo) at the first endoscopy. The patients with acute gastric ulcers were divided at random into age- and sex-matched 2 groups. Five patients (4 males and 1 female; mean age \pm SD, 54.4 \pm 12.4 years; PPI group) were administered rabeprazole (10 mg/day), while 6 (5 males and 1 female; 53.3 \pm 12.6 years; H₂ blocker group) were administered ranitidine (300 mg/day) for 8 weeks. The control group without any episode of gastric ulcer comprised 5 subjects (4 males and 1 female; 55.2 \pm 11.9 years) who were all positive for *Hp*. In the PPI group, one had diabetes mellitus, and one had bronchial asthma as complications of gastric ulcer. In the H₂ blocker group, one had hypertension, one had diabetes mellitus, and one had chronic bronchitis as complications. In the control group without any episode of gastric ulcer, one had hypertension and one had diabetes mellitus. The oral treatments for these complications were continued. The ulcer diameters and the blood hemoglobin levels at the first endoscopy were similar in all groups (Table 1). No patient had taken NSAIDs, PPIs, H₂ blockers, PG preparations, or antibiotics prior to enrollment in this study. Pa-

Table 1. Clinical characteristics of gastric ulcer patients (PPI and H₂ blocker groups) and nonulcer subjects (control group) with *Hp* infection

	PPI	H ₂ blocker	Control	P values
Male/female	4/1	5/1	4/1	NS
Age (years)	54.4 \pm 12.4	53.3 \pm 12.6	55.2 \pm 11.9	NS
Diameter of gastric ulcer (cm)	1.2 \pm 0.4	1.1 \pm 0.4	Not detected	NS
Blood hemoglobin level (g/dl)	15.9 \pm 2.7	15.8 \pm 2.4	15.5 \pm 3.1	NS

Values are the means \pm SD (n = 5 or 6).

tients with gastric or other cancers, liver disease, renal dysfunction, or duodenal ulcer were excluded. Informed consent was obtained from all of the subjects.

METHODS

At endoscopic examinations performed in the control group and in the antisecretory agents-groups before and at 8 and 12 weeks after beginning the administration of the antisecretory agents, tissue samples were collected both from the edge of the ulcer on the gastric angle (ulcerated areas) and the lower gastric body on the greater curvature (nonulcerated areas), and were immediately stored at -80C until assayed. The concentrations of PGE₂, 6-keto PGF_{1a}, which is a metabolic product of stable PGI₂, and LTB₄, and the gene expressions of COX-1 and COX-2 were examined in the gastric mucosa. *Hp* elimination treatment was performed at 12 weeks or more after beginning the administration of the antisecretory agents.

The biopsy specimens were homogenized in a Polytron PCU homogenizer (Kinematica, Luzern, Switzerland), the PGE₂ and 6-keto PGF_{1a} concentrations were determined using radioimmunoassay kits (Amersham, Little Chalfont, UK), and the LTB₄ concentration was determined using an enzyme immunoassay kit (Amersham). The protein concentration was determined by the Lowry protein assay. For RNA extraction from gastric mucosal tissue specimens after pooling the samples from the ulcerated and nonulcerated areas, 10 mg of the frozen gastric mucosal tissue was homogenized with a glass homogenizer in 200µl of RNAzolTM B (Biotex Laboratories, Friendswood, TX, USA) at 4C. Twenty microliters of phenol/chloroform were then added to the mixture and the aqueous phase was collected after centrifugation at 12,000 X g at 4C for 15 minutes. The RNA was precipitated with an equal volume of isopropanol and then it was washed with 75% ethanol. RNA pellets were resuspended in 20 µl of diethylpyrocarbonate-treated distilled water and stored at -80C. For the analysis of COX-2 mRNA and COX-1 mRNA expression, RT-PCR was performed using a one-step RNA PCR kit (AMV). Briefly, 1 µg of total RNA for each sample was added to a PCR reaction. After reverse transcription (30 min at 50 C ; 2 min at 94 C), 30 cycles of amplifications (1 min at 94 C ; 1 min at 50 C ; 1 min at 72 C) were performed. The linear range for PCR was found to be

between 20 and 40 cycle. The PCR products were separated on 2% agarose gel containing 0.5 µg/ml of ethidium bromide. The oligonucleotides, 5'-TGCCAGCTCCTGGCCCCGCCGCTT-3' and 5'-GTGCATCAACAGGCGCCTCTTC-3' were used for amplification of the 303 bp fragment of human COX-1 mRNA(12). The oligonucleotides, 5'-TTCAAATGAGATTGTGGGAAAAT-3' and 5'-AGATCATCTCTGCCTGAGTATCTT-3' were used for amplification of the 305 bp fragment of human COX-2 mRNA(12). Yeast transfer RNA was used as negative controls. Beta-actin gene expression was monitored for the control of mRNA loading. The expression intensities of COX-2 mRNA and COX-1 mRNA were evaluated by scanning densitometry (Gel Doc 1000UV, Richmond, CA, USA) in comparison to the intensity of beta-actin gene expression.

Statistical analysis

The results are expressed as the means ± SD. Differences between the groups were assessed by Student's *t* test. *P* values of <0.05 were considered to be significant.

RESULTS

In the PPI and H2 blocker groups of gastric ulcer patients with *Hp* infection before treatment with the antisecretory agents, the concentrations of PGE₂ (Fig. 1) and 6-keto PGF_{1a} (Fig. 2) in the gastric mucosa were significantly lower than those in the control group of nonulcer subjects with *Hp* infection, although the 6-keto PGF_{1a} concentration in the




Fig. 1. Changes in the gastric mucosal levels of PGE₂ after treatment with rabeprazole (PPI group) or ranitidine (H₂ blocker group)

The gastric ulcer base disappeared at 8 – 12 weeks after treatment. The samples were obtained from the gastric mucosa in ulcer patients and nonulcer subjects (control group). Values are the means ± SD (n = 5 or 6). **P* <0.05 in comparison with the control group. ***P* <0.05 in comparison with the H₂ blocker group.

nonulcerated gastric mucosa in ulcer patients did not show a significant decrease (Fig. 2). All of gastric ulcers had been already scarred (S2) 8 weeks after treatment with the antisecretory agents. During gastric ulcer healing, the PGE₂ concentration in the PPI group after 8 weeks increased significantly more than that in the H₂ blocker and control groups, and then returned after 12 weeks to a level similar to that in the H₂ blocker and control groups (Fig. 1). The 6-keto PGF_{1α} concentration in the ulcerated gastric mucosa in ulcer patients returned after 8 weeks to a level similar to that in the nonulcerated mucosa in both the ulcer patients and nonulcer subjects (Fig. 2). Whereas the LTB₄ (Fig. 3) concen-




Fig. 2. Changes in the gastric mucosal levels of 6-keto PGF_{1α} after treatment with rabeprazole (PPI group) or ranitidine (H₂ blocker group)

The gastric ulcer base disappeared at 8 – 12 weeks after treatment. The samples were obtained from the gastric mucosa in ulcer patients and nonulcer subjects (control group). Values are the means \pm SD (n = 5 or 6). *P < 0.05 in comparison with the control group.




Fig. 3. Changes in the gastric mucosal levels of LTB₄ after treatment with rabeprazole (PPI group) or ranitidine (H₂ blocker group)

The gastric ulcer base disappeared at 8 - 12 weeks after treatment. The samples were obtained from the gastric mucosa in ulcer patients and nonulcer subjects (control group). Values are the means \pm SD (n = 5 or 6). *P < 0.05 in comparison with the control group. *P < 0.05 in comparison with the H₂ blocker group. #P < 0.05 in comparison with the nonulcerated area in the same group of ulcer patients.

tration in ulcer patients before the antisecretory agent treatment was significantly higher than in that in nonulcer subjects, and it was significantly lower in the ulcerated mucosa than that in the nonulcerated mucosa. During gastric ulcer healing, the LTB₄ concentration of the ulcer-scarred and nonulcerated mucosa in the PPI group after 8 weeks decreased significantly more than that in the H₂ blocker and control groups without any significant difference between in the ulcer-scarred and nonulcerated mucosae, and then it returned after 12 weeks to a level similar to that in the H₂ blocker and control groups (Fig. 3).

The COX-1 mRNA expression level in the gastric mucosa showed no difference among the PPI, H₂ blocker and control groups or between before and after the treatment (Fig. 4). However, the COX-2 mRNA expression level in the gastric mucosa in ulcer patients was significantly reduced before the treatment in comparison with that in nonulcer subjects. Moreover, the relative densities of COX-2 PCR bands at 8 weeks were 2.8 times and 2.1 times increased in the PPI group and in the H₂ blocker group, respectively, and the increase was signifi-




Fig. 4. Changes in the gastric mucosal expressions of COX-1 mRNA after treatment with rabeprazole (PPI group, A) or ranitidine (H₂ blocker group, B)

The samples were obtained from the gastric mucosa in ulcer patients and nonulcer subjects (control group). Both tissue specimens obtained from the ulcerated and nonulcerated areas were mixed for RNA extraction. The levels of COX-1 gene expression (303 bp) and β -actin gene expression (125 bp) were analyzed by RT-PCR. The results of a densitometric analysis are presented as the mean percentages of the signal intensity of β -actin for COX-1 mRNA expression (C). Values are the means \pm SD (n = 5 or 6).

cantly greater in the PPI group. The COX-2 gene expression level in the PPI group returned after 12 weeks to a level similar to that in the H₂ blocker and control groups (Fig. 5).




Fig. 5. Changes in the gastric mucosal expressions of COX-2 mRNA after treatment with rabeprazole (PPI group, A) or ranitidine (H₂ blocker group, B)

The samples were obtained from the gastric mucosa from both ulcer patients and nonulcer subjects (control group). Both tissue specimens obtained from the ulcerated and nonulcerated areas were mixed for RNA extraction. The levels of COX-2 gene expression (305 bp) and β -actin gene expression (125 bp) were analyzed by RT-PCR. The results of a densitometric analysis are presented as the mean percentages of the signal intensity of β -actin for COX-2 mRNA expression (C). Values are the means \pm SD (n = 5). *P < 0.05 in comparison with the control group. †P < 0.05 in comparison with the H₂ blocker group.

DISCUSSION

PGs, which are mucosal protective factors, have an antisecretory effect as well as a mucosa-protecting effect(7, 13). PGs are produced from arachidonic acid released from phospholipids of biological membranes by the action of phospholipase. Phospholipids metabolize into PGs and LTs by the COX and lipoxygenase pathways, respectively. While COX-1 acts as a housekeeping enzyme in the gastric mucosa and platelets, COX-2, the expression of which is induced by agents including cytokines in such cells as macrophages and neutrophils, is known to play a role in inflammation and cell proliferation. NSAIDs reduce the PG production by inhibiting the expression of COX-1 and COX-2 in the gastric mucosa and by increasing LTs in relative terms

(14). A decrease in PGs depresses various factors in the gastric mucosal defense system, and an increase in LTs enhances the radical production while also exacerbating damage to the gastric mucosa (15). This study was initiated from based on the hypothesis that PPI promotes the healing mechanism of the gastric mucosa via the secretory kinetics of PGs and LTs by exerting some effect on the COX expression in not only NSAID-induced gastric ulcers, which we experienced(11), but also in common gastric ulcers. The mucosal protecting effects of PGs against various agents that induce damage to the gastric mucosa are called cytoprotection. PGs produce effects such as directly protecting cells and promoting cytotoxicity in the luminal cavity, epithelial, and subepithelial levels(14). Particularly, PGE₂ increases the mucosal blood flow, promotes mucus secretion, and increases bicarbonate secretion (16), while PGI₂ suppresses gastric acid secretion (17). In addition, *Hp* infection is associated with an increased production of PGE₂ in the gastric mucosa (18). *Hp* infection elicits persistent neutrophil infiltration in the gastric mucosa. The COX-2 expression by the neutrophils results in PGE₂ synthesis (19). In this study, the PGE₂ and 6-keto PGF_{1 α} (a metabolic product of stable PGI₂) concentrations in ulcer patients with *Hp* infection decreased during the active-ulcer stage, and thereafter increased during the ulcer-healing stage after treatment with PPI and H₂ blocker to a level similar to those in nonulcer subjects with *Hp* infection. Moreover, the increase in the PGE₂ concentration after 8 weeks, when the gastric ulcers had been already scarred, was significantly greater in the PPI group than in the H₂ blocker group. In contrast, the 6-keto PGF_{1 α} concentration after 8 weeks showed no significant difference between the PPI, H₂ blocker and control groups, when comparing the findings before and after the treatment.

Kobayashi, *et al.* reported the PG levels to increase at 4 and 7 days post-polypectomy in patients in whom gastric ulcers were produced by an electric burning resection of gastric polyps, while the most remarkable increase took place in the mucosa along the ulcer margin rather than the mucosa far from the ulcer site(20). In the present study, however, the PGE₂ and 6-keto PGF_{1 α} levels were the lowest during the active-ulcer stage with no significant difference between the ulcerated and nonulcerated mucosae, although the 6-keto PGF_{1 α} level in the ulcerated mucosa was significantly lower than that in the control group. In addition, Kobayashi, *et*

al. also reported that the PGE₂ level in chronic gastric ulcer patients was not significantly different from that in normal subjects(21). Since chronic *Hp* infection is accompanied by a persistent mucosal production of PGE₂(18), the PG production mechanisms might therefore be depleted when a gastric ulcer breaks out, although this study could not show any comparative information on the degree of gastric mucosal inflammation between the gastric ulcer groups.

LTs are synthesized in leukocytes as arachidonic acid is metabolized by lipoxygenase. An increase in LTs enhances the radical production and aggravates damage to the gastric mucosa(22). LTC₄, LTD₄, and LTE₄ enhance capillary permeability and promote airway mucosal secretion. LTB₄ promotes leukocytotaxis(23). In our study, the LTB₄ concentration increased during the active-ulcer stage in ulcer patients, and it decreased during the ulcer-healing stage after the treatment. The decrease in the LTB₄ concentration of the ulcer-scarred and nonulcerated mucosae was significantly greater in the PPI group than in the H₂ blocker group after 8 weeks, thus suggesting that PPI could reduce the LTB₄ production in the stomach.

COX-1 is routinely expressed in the normal gastric mucosa, but COX-2 is expressed in the lamina propria mucosae in the gastric mucosa infected by *Hp* (24, 25). In experimental erosion or ulcer created in animals, COX-2 mRNA and COX-2 protein have been reported to be expressed in ulcer margins, while a COX-2 inhibitor was said to delay the cure of ulcers(26, 27). Although whether selective COX-2 inhibitors could induce directly gastrointestinal ulceration remains to be elucidated, these findings suggest that COX-2 could play an important role in the repair of gastric ulcers by regulating PG biosynthesis. In this study, gastric ulcer patients with *Hp* infection showed significant difference in the COX-2 mRNA expressions between the acute and scarring phases during gastric ulcer healing. The mucosal expression of COX-2 mRNA increased 2.8 times at 8 weeks after the beginning of the treatment in the PPI group, and this increase was significantly greater than that in the H₂ blocker group. The COX-1 gene expression showed no significant difference between the PPI and H₂ blocker groups or when comparing the findings before and after the treatment.

These results suggest that rabeprazole has a mucosa-protecting effect on the healing process of ulcers by increasing the PGE₂ production and re-

ducing the LTB₄ production. In addition, rabeprazole has a unique pharmacological ability to augment the production of gastric mucus and mucin which thus generate the so-called mucus buffer layer covering the gastric mucosa(28). PPIs have been reported to inhibit radical production and inflammation by suppressing the neutrophil activity(29-31). Akimoto, *et al.* reported that rabeprazole is able to promote vessel regeneration and maturation, thereby facilitating ulcer healing(32). In ulcer patients, the increase of basic fibroblast growth factor was reported to be greater with PPIs than H₂ blockers(33). Although the mechanisms by which rabeprazole induces COX-2 and PGE₂ production and reduces LTB₄ production remain to be elucidated in gastric ulcer patients with *Hp* infection, it is considered to promote the healing of ulcers due to these mucosa-protecting actions in addition to its antisecretory action.

REFERENCES

1. Sachs G : Proton pump inhibitors and acid-related diseases. *Pharmacotherapy* 17 : 22-37, 1997
2. Mattsson H, Andersson K, Larsson H : Omeprazole provides protection against experimentally induced gastric mucosal lesions. *Eur J Pharmacol* 91 : 111-114, 1983
3. Konturek SJ, Brzozowski T, Radecki T : Protective action of omeprazole, a benzimidazole derivative, on gastric mucosal damage by aspirin and ethanol in rats. *Digestion* 27 : 159-164, 1983
4. Watanabe T, Higuchi K, Tominaga K, Fujiwara Y, Arakawa T : Cytoprotective effect of rabeprazole against ethanol-induced gastric mucosal damage : possible involvement of nitric oxide. *Drugs Exp Clin Res* 26 : 41-45, 2000
5. Tsuji S, Sun WH, Tsujii M, Kawai N, Kimura A, Kakiuchi Y, Yasumaru S, Komori M, Murata H, Sasaki Y, Kawano S, Hori M : Lansoprazole induces mucosal protection through gastrin receptor-dependent up-regulation of cyclooxygenase-2 in rats. *J Pharmacol Exp Ther* 303 : 1301-1308, 2002
6. Smith WL, Garavito RM, DeWitt DL : Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. *J Biol Chem* 271 : 33157-33160, 1996
7. Robert A, Nezamis JE, Lancaster C, Davis JP, Field SO, Hanchar AJ : Mild irritants prevent

- gastric necrosis through "adaptive cytoprotection" mediated by prostaglandins. *Am J Physiol* 245 : G113-G121, 1983
8. Mizuno H, Sakamoto C, Matsuda K, Wada K, Uchida T, Noguchi H, Akamatsu T, Kasuga M : Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. *Gastroenterology* 112 : 387-397, 1997
 9. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN : Leukotrienes and lipoxins : structures, biosynthesis, and biological effects. *Science* 237 : 1171-1176, 1987
 10. Serhan CN, Haeggstrom JZ, Leslie CC : Lipid mediator networks in cell signaling : update and impact of cytokines. *FASEB J* 10 : 1147-1158, 1996
 11. Shimizu I, Horie T, Inoue H, Oshima T, Fujimoto M, Ozaki Y, Yamamoto K, Iuchi A, Ito S : Penetration by a giant gastric ulcer induced by a nonsteroidal anti-inflammatory drug. *Endoscopy* 32 : 539-541, 2000
 12. Hla T, Neilson K : Human cyclooxygenase-2 cDNA. *Proc Natl Acad Sci USA* 89 : 7384-7388, 1992
 13. Miller TA : Protective effects of prostaglandins against gastric mucosal damage : current knowledge and proposed mechanisms. *Am J Physiol* 245 : G601-G623, 1983
 14. Wallace JL, Tigley AW : Review article : new insights into prostaglandins and mucosal defence. *Aliment Pharmacol Ther* 9 : 227-235, 1995
 15. Asako H, Kubes P, Wallace J, Gaginella T, Wolf RE, Granger DN : Indomethacin-induced leukocyte adhesion in mesenteric venules : role of lipoxygenase products. *Am J Physiol* 262 : G903-G908, 1992
 16. Gudis K, Sakamoto C : The role of cyclooxygenase in gastric mucosal protection. *Dig Dis Sci* 50 (Suppl 1) : S16-S23, 2005
 17. Kauffman GL, Zhang L, Xing LP, Seaton J, Colony P, Demers L : Central neurotensin protects the mucosa by a prostaglandin-mediated mechanism and inhibits gastric acid secretion in the rat. *Ann NY Acad Sci* 597 : 175-190, 1990
 18. Hudson N, Balsitis M, Filipowicz F, Hawkey CJ : Effect of *Helicobacter pylori* colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. *Gut* 34 : 748-751, 1993
 19. Kim JS, Kim JM, Jung HC, Song IS : Expression of cyclooxygenase-2 in human neutrophils activated by *Helicobacter pylori* water-soluble proteins : possible involvement of NF-kappaB and MAP kinase signaling pathway. *Dig Dis Sci* 46 : 2277-2284, 2001
 20. Kobayashi K, Arakawa T, Nakamura H, Chono S, Yamada H, Satoh H, Kamata T, Ono T : Protective action of endogenous prostacyclin (PGI₂) and prostaglandin E₂ (PGE₂) in endoscopic polypectomy-induced human ulcers. *Gastroenterol Jpn* 17 : 430-433, 1982
 21. Kobayashi K, Arakawa T, Nakamura H, Chono S, Yamada H, Kamata T, Ono T : Role of prostaglandin E₂ on human gastric ulcers. *Gastroenterol Jpn* 17 : 21-24, 1982
 22. Peskar BM : Leukotrienes in mucosal damage and protection. *J Physiol Pharmacol* 42 : 135-145, 1991
 23. Pihan G, Rogers C, Szabo S : Vascular injury in acute gastric mucosal damage. Mediator role of leukotrienes. *Dig Dis Sci* 33 : 625-632, 1988
 24. Takahashi S, Shigeta J, Inoue H, Tanabe T, Okabe S : Localization of cyclooxygenase-2 and regulation of its mRNA expression in gastric ulcers in rats. *Am J Physiol* 275 : G1137-G1145, 1998
 25. Tatsuguchi A, Sakamoto C, Wada K, Akamatsu T, Tsukui T, Miyake K, Futagami S, Kishida T, Fukuda Y, Yamanaka N, Kobayashi M : Localisation of cyclooxygenase 1 and cyclooxygenase 2 in *Helicobacter pylori* related gastritis and gastric ulcer tissues in humans. *Gut* 46 : 782-789, 2000
 26. Shigeta J, Takahashi S, Okabe S : Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. *J Pharmacol Exp Ther* 286 : 1383-1390, 1998
 27. Brzozowski T, Konturek PC, Konturek SJ, Schuppan D, Drozdowicz D, Kwiecien S, Majka J, Nakamura T, Hahn E : Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and -2. *Digestion* 64 : 15-29, 2001
 28. Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J : Significant enhancement of gastric mucin content after rabeprazole administration : its potential clinical significance in acid-related disorders. *Dig Dis Sci* 48 : 322-328, 2003
 29. Wandall JH : Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. *Gut* 33 : 617-621, 1992

30. Suzuki M, Mori M, Miura S, Suematsu M, Fukumura D, Kimura H, Ishii H : Omeprazole attenuates oxygen-derived free radical production from human neutrophils. *Free Radic Biol Med* 21 : 727-731, 1996
31. Lapenna D, de GS, Ciofani G, Festi D, Cucurullo F : Antioxidant properties of omeprazole. *FEBS Lett* 382 : 189-192, 1996
32. Akimoto M, Hashimoto H, Shigemoto M, Maeda A, Yamashita K : Effects of antisecretory agents on angiogenesis during healing of gastric ulcers. *J Gastroenterol* 40 : 685-689, 2005
33. Tsuji S, Kawano S, Tsujii M, Michida T, Masuda E, Gunawan ES, Hori M : Mucosal microcirculation and angiogenesis in gastrointestinal tract. *Jpn J Clin Med* 56 : 2247-2252, 1998